PA
NAUT icon

Parallel Advisors’s Nautilus Biotechnolgy NAUT Stock Holding History

Parallel Advisors’s Portfolio NAUT Stock Details NAUT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-363
Closed -$1K – 3464
2022
Q3 		$1K Buy
+363
New +$913 ﹤0.01% 2966

Other funds holding NAUT

PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
CM
Cercano Management Bellevue, Washington $2.32B AUM 30.12% 1-Year Est. Return
MVG
Madrona Venture Group Seattle, Washington $22.1M AUM 86.9% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
CFM
Comprehensive Financial Management Los Gatos, California $3.01B AUM 2.93% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
TM
Tikvah Management Charlotte, North Carolina $323M AUM 69.61% 1-Year Est. Return
ACI
Amazon.com Inc Seattle, Washington $2.63B AUM 20.53% 1-Year Est. Return
AI
ArchPoint Investors Coral Gables, Florida $420M AUM 42.19% 1-Year Est. Return

Parallel Advisors's NAUT Position: Q4 2022 in Review

Parallel Advisors sold out of Nautilus Biotechnolgy (NAUT) in Q4 2022, closing a stake of 363 shares — an estimated $1K sold.

Parallel Advisors first reported a position in NAUT in Q3 2022 and held it in 1 quarter. The position peaked at $1K in Q3 2022. 81 funds tracked by Wall St. Rank hold NAUT as of Q4 2022.

  • Parallel Advisors reported no remaining Nautilus Biotechnolgy position as of Q4 2022 after selling out during the quarter.
  • Parallel Advisors sold 363 Nautilus Biotechnolgy shares in Q4 2022, an estimated $1K.
  • Parallel Advisors first reported a position in Nautilus Biotechnolgy in Q3 2022 and held it in 1 quarter.
  • Parallel Advisors's Nautilus Biotechnolgy position peaked at $1K in Q3 2022.
  • 81 funds tracked by Wall St. Rank held Nautilus Biotechnolgy as of Q4 2022.

Based on Parallel Advisors's 13F filing for Q4 2022, filed 6 Feb 2023.